The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

By T. D. Henry, B. Annex, G. McKendall, M. Azrin, John J. Lopez, F. Giordano, P. K. Shah, J. Willerson, R. Benza, D. Berman and 5 more. 2003

1,074 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/a3d0783fc1baf30df7a6ff437e017c81d2ed3aea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Ferrara
2. H. Gerber
3. R. Kerbel
4. J. Lecouter
5. Rakesh K. Jain
6. Peter Carmeliet
7. A. Adamis
8. J. Joyce

Citations in the corpus

• The biology of VEGF and its receptors (2003, result): “Thus far, clinical results with VEGF (or basic FGF) have been somewhat disappointing because the treatment did not significantly increase exercise treadmill time, although some improvement in angina class was measured in a placebo-controlled trial with recombinant VEGF 165 in coronary ischemia pati”
• Angiogenesis as a therapeutic target (2005, result): “Although promising results were initially reported in small open-label trials, none of the placebo-controlled trials so far conducted with recombinant proteins or gene therapy has yielded convincingly positive result”